AVANT Immunotherapeutics, Inc. (AVAN) Surges on Pfizer Agreement
Avant Immunotherapeutics(AVAN:NASDAQ) discovers and develops innovative vaccines and targeted immunotherapeutics for the treatment of cancer and infectious and inflammatory diseases. On March 7th ,the company announced a completed merger with Celldex Therapeutics. The resultant merged company has three commercialized products and a deep pipeline of six products in the development stage. On Thursday April 17th, shares of Avant surged after the company announced a licensing and development agreement with Pfizer. Pfizer will be granted an exclusive worldwide license to a cancer vaccine candidate, CDX-110. This vaccine is in Phase 2 development for the treatment of glioblastoma multiforme which is the…